D-23129: A new anticonvulsant compound

CNS Drug Reviews

Volumn 2, Issue 3, 1996, Pages 308-321

  Kapetanovic, Izet M ^a   Rundfeldt, Chris ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b ASTA MEDICA AG   (Germany)

Author keywords

Animal models; Anticonvulsant; Antiepileptic; D23129; Electrophysiology; GABA; Glutamate; H ippocampus; Kainate; Kindling; Potassium; Seizures; Slices

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; RETIGABINE; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; ARTICLE; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; EPILEPSY; NONHUMAN;

EID: 0029855407     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00304.x     Document Type: Article

References (42)

1. Alger BE. Hippocampus: Electrophysiological studies of epileptiform activity in vitro. In: Dingledine R, ed. Brain Slices. New York: Plenum Press, 1984:155-199.
2. Dailey JW, Cheong JH, Ko KH, Adams-Curtis LE, Jobe PC. Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: Prediction of clinical response. Neurosci Lett 1995;195:77-80.
3. Dailey JW, Jobe PC. Anticonvulsant drugs and the genetically epilepsy-prone rat. Fed Proc 1985;44:2640-2644.
4. Engel J. Clinical aspects of epilepsy. Epilepsy Res 1991;10:9-17.
5. Friedel HA, Fitton A. Flupirtine: A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45:548-569.
6. Ganguly A, Wolf HH, White HS. Investigational anticonvulsant D-23129 inhibits limbic behavioral seizures in hippocampal kindled rats. Epilepsia (Suppl 4) 1995;36:49.
7. Jainta H, Tober C, Kronhach T. Exploratory pharmacokinetics of the new anticonvulsant D-23129 in rats and dogs investigated by column-switching HPLC. Naunyn Schmiedeberg's Arch Pharmacol (Suppl) 1995;351:R51.
8. Kapetanovic IM, Yonekawa WD, Kupferberg HJ. The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vivo. Epilepsy Res 1995;22:167-173.
9. Kapetanovic IM, Yonekawa WD, Kupferberg HJ. Time-related loss of glutamine from hippocampal slices and concomitant changes in neurotransmitter amino acids. J Neurochem 1993;61:885-872.
10. Kupferberg HJ. Animal models for identifying new anticonvulsant drugs. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. Philadelphia: Lea & Febiger, 1993:743-751.
11. Kupferberg HJ. Antiepileptic drug development program: A cooperative effort of government and industry. Epilepsia (Suppl 1) 1989;30:S51-S56.
12. Lang DC, Wang CM, Cooper BR. Lamotrigine, phenytoin, and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993;286:829-835.
13. Leung LS, Fu XW. Factors affecting paired-pulse facilitation in hippocampal CA1 neurons in vitro. Brain Res 1994;650:75-84.
14. Löscher W, Schmidt D. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res 1994;17:95-134.
15. Löscher W, and Nolting B. The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991;9:1-10.
16. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:145-181.
17. Lynch G, Schubert P. The use of m vitro brain slices for multidisciplinary studies of synaptic function. Ann Rev Neurosci 1980;3:1-22.
18. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992, 260:1166-1173.
19. McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes 1996 (submitted for publication).
20. Meldrum BS. Pharmacological approaches to the treatment of epilepsy. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs. London: John Libbey 1986:17-30.
21. Mengel H. Tiagabine. Epilepsia (Suppl 5) 1994;35:S81-S84.
22. Nickel B, Shandra A, Godlevsky L, Mazarati A, Kupferberg H, Szelenyi I. Anticonvulsant activity, of D-20443. Naunyn Schmiedeberg's Arch Pharmacol (Suppl) 1993;347:R142.
23. Nickel B, Shandra A, Godlevsky L, Mazarati A, Kupferberg H, Szelenyi I. Antiepileptic effects of a new drug: D-20443. Epilepsia (Suppl) 1993;34:95.
24. Perreault P, Avoli M. Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. J Neurophysiol 1991;65:771-785.
25. Porter RJ. Classification of epileptic seizures and epileptic syndromes. In: Laidlaw J, Richens A, Chadwick D, eds. A Textbook of Epilepsy. New York: Churchill Livingstone, 1993:1-22.
26. Racine RJ, Livingston K, Joaquin A. Effects of procaine hydrochloride, diazepam and diphenylhydantoin on seizure development in cortical and subcortical structures in rats. Electroencephalograph Clin Neurophysiol 1975;38:355-365.
27. Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-223.
28. Rundfeldt C, Rohlfs A, Netzer R. Multiple actions of the new anticonvulsant D-23129 on voltage-gated inward currents and GABA-induced currents in cultured neuronal cells. Naunyn Schmiedeberg's Arch Pharmacol (Suppl) 1995;351:R160.
29. Rundfeldt C, Tober C, Ganguly A, Wolf HH, White HS. Potassium channel opening properties of D-23129, an anticonvulsant with potent effects in rodent models for generalized and focal seizures. Soc Neurosci Abstr 1995;21:203.
30. Seaman CA, Sheridan PH, Engel J, Molliere M, Narang PK, Nice FJ. Flupirtine. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs. London: Libbey 1986:135-146.
31. Seydel JK, Schaper KJ, Coats EA, et al. Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines. J Med Chem 1994;37:3016-3022.
32. Silver JM, Shin C, McNamara JO. Antiepileptogenic effects of conventional anticonvulsants in the kindling model at epilepsy. Annals Neurol 1991;29:356-363.
33. Skeen GA, Wolf HH, White HS. D-23129 attenuates glutamate-evoked whole cell currents of mouse cortical neurons through an interaction with kainate-sensitive ion channels. Soc Neurosci Abstr 1995;21:353.
34. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-169.
35. Tober C, Jainta H, Rundfeldt C, Rostock A, Bartsch R. Anticonvulsant and antiepileptogenic effects of D-23129 in the kindling model of focal epilepsy. Naunyn Schmiedeberg's Arch Pharmacol (Suppl) 1995;351:R160.
36. Tober C, Rostock A, Bartsch R. The phenylcarbamic acid ester D-23129 is highly effective against amygdala kindled seizures in rats. Eur J Pharmacol (Suppl) 1994;7:212.
37. Tober C, Rundfeldt C, Rostock A, Bartsch R. The phenyl carbamic acid ester D-23129 is highly effective in epilepsy models for generalized and focal seizures at nontoxic doses. Soc Neurosci Abstr 1994;20:1641.
38. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992;35:564-572.
39. Yamaguchi S, Rogawski MA. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice Epilepsy Res 1992;11:9-16.
40. Yonekawa WD, Kapetanovic IM, Kupferberg HJ. The effects of D-23129 (ADD 230001) and standard anticonvulsants on the paired-pulse paradigm in rat hippocampus in vitro. Soc Neurosci Abstr 1995;21:2117.
41. Yonekawa WD, Kapetanovic IM, Kupferberg HJ. The effects of anticonvulsant agents on 4-aminopyridine-induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res 1995;20:137-150.
42. Zhao D, Leung LS. Partial hippocampal kindling increases paired-pulse facilitation and burst frequency in hippocampal CA1 neurons. Neurosci Lett 1993;154:191-194.